COMMUNIQUÉS West-GlobeNewswire

IBA SA – NOTIFICATION TRANSPARENCE
12/01/2026
(article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes) Louvain-la-Neuve, Belgique, le 12 janvier 2026, 18:00 Résumé de la notification IBA (Ion Beam Applications SA), le [...]
SAFE GROUP NOMME CYRIL GONCALVES AU POSTE DE DIRECTEUR ADMINISTRATIF ET FINANCIER
12/01/2026
SAFE GROUP NOMME CYRIL GONCALVES AU POSTE DE DIRECTEUR ADMINISTRATIF ET FINANCIER Renforcement de l’équipe de direction Fleurieux-sur-l’Arbresle – France – 12 janvier 2026 – 18h - Safe (FR001400ZU25 – ALSAF), annonce [...]
Oncovita announces a strategic partnership with Infinitusbio.AI to explore the design and optimize the development of new therapeutic candidates from its Measovir® platform.
12/01/2026
Oncovita announces a strategic partnership with Infinitusbio.AI to explore the design and optimize the development of new therapeutic candidates from its Measovir® platform. San Diego, United-States and Paris, France – [...]
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
12/01/2026
Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both treatment-naïve and previously-treated nusinersen patients with SMA 1 Biogen is dedicated to [...]
BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference
12/01/2026
- Preliminary unaudited Q4 and Full Year 2025 net Attruby ® product revenue of $146.0 million and $362.4 million, respectively - Attruby (acoramidis) is rapidly becoming the first-choice therapy for newly diagnosed ATTR [...]
SafeSpace Global Corporation (OTCID: SSGC) Issues CEO Letter to Shareholders
12/01/2026
Knoxville, TN, Jan. 12, 2026 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation (OTCID: SSGC), a leading AI technology company delivering multimodal safety solutions across education, healthcare, transportation, and [...]
Press Release Biocartis NV: Biocartis to collaborate with Mayo Clinic on breast cancer gene signatures
12/01/2026
PRESS RELEASE, 01/12/2026, 10:00 EST Biocartis to collaborate with Mayo Clinic on breast cancer gene signatures Itasca, IL, US, 12 January 2026 – Biocartis announced today that it has entered into a research [...]
Acentra Health Honored as One of Modern Healthcare’s 2025 Best in Business
12/01/2026
The company earned recognition in the highly competitive Healthcare IT category for its configurable, modular solutions MCLEAN, Va., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Acentra Health , a technology and health solutions [...]
Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference
12/01/2026
VERO BEACH, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced that [...]
PacBio Announces Plans for Collaboration With n-Lorem Foundation and EspeRare to Advance Precision Therapies for Rare Genetic Diseases
12/01/2026
The planned collaboration highlights the role of complete genome resolution in scaling n-of-1 therapeutic models MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most [...]
Global Alzheimer’s Platform Foundation Announces Strategic Collaboration and Partnership with Spear Bio for the Transformative Bio-Hermes-002 Study
12/01/2026
Spear Bio joins collaborative study focused on new biomarkers designed to improve diagnosis of Alzheimer's disease and dementias WASHINGTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation [...]
Omada Health Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2025
12/01/2026
SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced preliminary, unaudited revenue for the fourth quarter and fiscal year ended [...]
PacBio HiFi Adopted as First-Line Sequencing Approach to Investigate Sudden Unexplained Death in Childhood (SUDC)
12/01/2026
Trios from 200 families who have lost a child to SUDC to be sequenced on PacBio’s Revio system with SPRQ-Nx chemistry, enabling increased diagnostic yield for grieving families MENLO PARK, Calif., Jan. 12, 2026 (GLOBE [...]
PacBio Announces Preliminary Fourth Quarter and Full Year 2025 Revenue
12/01/2026
Q4 2025 revenue growth of 14% year-over-year, driven by strong Revio and Vega shipments and record consumables revenue MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of [...]
InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)
12/01/2026
The CGuard ® Prime Carotid Stent System demonstrated the lowest 30-day and 1-year primary endpoint major adverse event rates of any pivotal study of carotid stenting (CAS) MIAMI, Jan. 12, 2026 (GLOBE NEWSWIRE) -- [...]
Helsinn announces new Executive Leadership Team as it celebrates 50 years
12/01/2026
Lugano, Switzerland – January 12th, 2026 – Helsinn Healthcare, a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, announces a new Executive Leadership Team as the company [...]
AOP Health’s Rapiblyk™ Now Accessible via Leading US Healthcare Improvement Companies
12/01/2026
WILMINGTON, Del., Jan. 12, 2026 (GLOBE NEWSWIRE) -- AOP Health US, LLC announced today that Rapiblyk™ (landiolol) is now more widely available across the United States through Cardinal, Cencora Specialty Distribution, [...]
SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025
12/01/2026
Fiscal Year 2025 worldwide revenue of $200.8 to $200.9 million, representing growth of ~20% SANTA CLARA, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural [...]
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk
12/01/2026
First BGE-102 MAD cohort completed in obese individuals with elevated hsCRP receiving 120 mg QD; demonstrated rapid and profound reduction in inflammatory markers BGE-102 achieved 86% reduction in hsCRP at Day 14, with [...]

Pages